低中所得国の医薬品アクセス、日本企業の最高は武田9位

A recent Nikkei article covers the Access to Medicine Foundation's new report, which assesses how major pharmaceutical companies are improving access in low- and middle-income countries (LMICs). The article focuses on the analysis of Japanese companies included in the report.

The article provides an overview of the performance of Japanese companies in the 2024 Index, with Takeda ranked 9th, Eisai 14th, Astellas Pharma 15th, and Daiichi Sankyo 18th. It highlights Takeda for its governance system and efforts in transferring manufacturing technology for vaccines and other products. Eisai, meanwhile, is noted for its commitment to providing medicines for neglected tropical diseases.

"Many of the global pharmaceutical companies that rank highly in the Index have offices and do business in low- and middle-income countries as well," quotes Marijn Verhoef, Director of Operations at the Foundation. "We would like Japanese pharmaceutical companies to consider expanding the areas they cover by setting up bases or collaborating with partners to offer more options to people in low- and middle-income countries."